Benzinga
Published Oct 30, 2023 16:00
Updated Oct 30, 2023 17:10
Assessing Biogen's Performance Against Competitors In Biotechnology Industry
Benzinga - by Benzinga Insights, Benzinga Staff Writer.
Amidst the fast-paced and highly competitive business environment of today, conducting comprehensive company analysis is essential for investors and industry enthusiasts. In this article, we will delve into an extensive industry comparison, evaluating Biogen (NASDAQ:BIIB) in comparison to its major competitors within the Biotechnology industry. By analyzing critical financial metrics, market position, and growth potential, our objective is to provide valuable insights for investors and offer a deeper understanding of company's performance in the industry.
Biogen Background Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.
Biogen Inc | 12.79 | 2.35 | 3.42 | 4.19% | $0.87 | $1.86 | -5.14% |
AbbVie Inc | 28.59 | 19.06 | 4.40 | 15.4% | $5.42 | $9.62 | -4.92% |
Amgen Inc | 17.63 | 20.63 | 5.29 | 22.74% | $3.26 | $5.17 | 5.94% |
Gilead Sciences Inc | 17.61 | 4.51 | 3.53 | 4.96% | $2.5 | $5.16 | 5.42% |
Vertex Pharmaceuticals Inc | 27.46 | 5.93 | 9.72 | 6.12% | $1.21 | $2.18 | 13.52% |
Regeneron Pharmaceuticals Inc | 20.51 | 3.51 | 6.96 | 4.08% | $1.2 | $2.75 | 10.53% |
Moderna Inc | 24.97 | 1.61 | 2.71 | -7.71% | $-1.64 | $-0.41 | -93.08% |
BioNTech SE | 4.78 | 1.04 | 2.28 | -0.95% | $-0.38 | $-0.37 | -94.75% |
Biomarin Pharmaceutical Inc | 155.13 | 3.17 | 6.89 | 1.19% | $0.1 | $0.47 | 11.52% |
Incyte Corp | 32.23 | 2.48 | 3.37 | 4.42% | $0.3 | $0.89 | 4.74% |
Neurocrine Biosciences Inc | 59.60 | 5.59 | 6.43 | 5.4% | $0.13 | $0.44 | 19.7% |
United Therapeutics Corp | 12.42 | 1.90 | 5.13 | 4.92% | $0.36 | $0.53 | 27.76% |
Exelixis Inc | 40.42 | 2.55 | 3.84 | 3.19% | $0.08 | $0.45 | 12.02% |
Grifols SA | 43.37 | 0.86 | 0.78 | 1.02% | $0.25 | $0.62 | 7.81% |
Average | 37.29 | 5.6 | 4.72 | 4.98% | $0.98 | $2.12 | -5.68% |
th, td { padding: 8px; text-align: left; }
th { background-color: #293a5a; color: #fff; text-align: left; }
tr:nth-child(even) { background-color: #f2f4f8; }
tr:hover { background-color: #e1e4ea; }
td:nth-child(3), td:nth-child(5) { text-align: left; }
.dividend-amount { font-weight: bold; color: #0d6efd; }
.dividend-frequency { font-size: 12px; color: #6c757d; } When closely examining Biogen, the following trends emerge:
The debt-to-equity (D/E) ratio is a measure that indicates the level of debt a company has taken on relative to the value of its assets net of liabilities.
Considering the debt-to-equity ratio in industry comparisons allows for a concise evaluation of a company's financial health and risk profile, aiding in informed decision-making.
In terms of the Debt-to-Equity ratio, Biogen can be assessed by comparing it to its top 4 peers, resulting in the following observations:
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Read the original article on Benzinga
Written By: Benzinga
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.